A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Klink, Barbara ^a   Miletic, Hrvoje ^b,c   Stieber, Daniel ^d   Huszthy, Peter C ^b,e   Valenzuela, Jaime Alberto Campos ^a   Balss, Jörg ^f   Wang, Jian ^b   Schubert, Manja ^g   Sakariassen, Per Øystein ^b   Sundstrøm, Terje ^b,g   Torsvik, Anja ^b   Aarhus, Mads ^h   Mahesparan, Rupavathana ^g   von Deimling, Andreas ^f,i   Kaderali, Lars ^a   Niclou, Simone P ^d   Schröck, Evelin ^a   Bjerkvig, Rolf ^b,d   Nigro, Janice M ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^e UNIVERSITY OF RIJEKA   (Croatia)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; HISTIDINE; TUMOR PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VESSEL; CANCER CELL; CANCER GRADING; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CIC GENE; CORPUS CALLOSUM; EXOME; FEMALE; FUBP1 GENE; GENE MUTATION; GENE SEQUENCE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IDH1 GENE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEWBORN; NONHUMAN; OLIGODENDROGLIOMA; RAT; SOMATIC MUTATION; TUMOR GENE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; WHITE MATTER;

ANIMALS; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DNA FINGERPRINTING; DNA HELICASES; DNA PRIMERS; DNA-BINDING PROTEINS; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED NOD; MICE, SCID; MICROARRAY ANALYSIS; MOLECULAR SEQUENCE DATA; OLIGODENDROGLIOMA; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, DNA; TRANSPLANTATION, HETEROLOGOUS;

EID: 84875113616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059773     Document Type: Article

References (46)

1. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, et al. (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473-1479.
2. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, et al. (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333: 1453-1455.
3. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, et al. (2011) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226: 7-16.
4. Liu J, Kouzine F, Nie Z, Chung HJ, Elisha-Feil Z, et al. (2006) The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c-myc expression. EMBO J 25: 2119-2130.
5. Jimenez G, Shvartsman SY, Paroush Z, (2012) The Capicua repressor - a general sensor of RTK signaling in development and disease. J Cell Sci 125: 1383-1391.
6. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
7. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
8. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
9. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, et al. (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483: 474-478.
10. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, et al. (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: 479-483.
11. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, et al. (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602.
12. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, et al. (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118: 469-474.
13. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H, (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153.
14. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, et al. (2012) Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol 107: 197-205.
15. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, et al. (2012) Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 4: 116ra114.
16. Choi C, Ganji SK, Deberardinis RJ, Hatanpaa KJ, Rakheja D, et al. (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18: 624-629.
17. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A, (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118: 599-601.
18. Branle F, Lefranc F, Camby I, Jeuken J, Geurts-Moespot A, et al. (2002) Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95: 641-655.
19. Claes A, Schuuring J, Boots-Sprenger S, Hendriks-Cornelissen S, Dekkers M, et al. (2008) Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol 18: 423-433.
20. Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, et al. (2009) Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia 11: 485-496.
21. Kelly JJ, Blough MD, Stechishin OD, Chan JA, Beauchamp D, et al. (2010) Oligodendroglioma cell lines containing t(1;19) (q10;p10). Neuro Oncol 12: 745-755.
22. Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, et al. (2011) An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol 14: 184-191.
23. Prochazka M, Gaskins HR, Shultz LD, Leiter EH, (1992) The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc Natl Acad Sci U S A 89: 3290-3294.
24. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, et al. (2009) IDH1 mutations at residue p. R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30: 7-11.
25. Balss J, Pusch S, Beck AC, Herold-Mende C, Kramer A, et al. (2012) Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. Acta Neuropathol.
26. Niclou SP, Danzeisen C, Eikesdal HP, Wiig H, Brons NH, et al. (2008) A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. Faseb J 22: 3120-3128.
27. Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, et al. (2012) CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 123: 853-860.
28. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, et al. (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475: 101-105.
29. Shoshan Y, Nishiyama A, Chang A, Mork S, Barnett GH, et al. (1999) Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci U S A 96: 10361-10366.
30. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, et al. (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15: 1913-1925.
31. Kitange G, Misra A, Law M, Passe S, Kollmeyer TM, et al. (2005) Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer 42: 68-77.
32. Smith JS, Wang XY, Qian J, Hosek SM, Scheithauer BW, et al. (2000) Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 59: 495-503.
33. Glass R, Synowitz M, Kronenberg G, Walzlein JH, Markovic DS, et al. (2005) Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J Neurosci 25: 2637-2646.
34. Alliot F, Rutin J, Leenen PJ, Pessac B, (1999) Pericytes and periendothelial cells of brain parenchyma vessels co-express aminopeptidase N, aminopeptidase A, and nestin. J Neurosci Res 58: 367-378.
35. Dahlstrand J, Collins VP, Lendahl U, (1992) Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 52: 5334-5341.
36. Calatozzolo C, Maderna E, Pollo B, Gelati M, Marras C, et al. (2006) Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. Cancer Biol Ther 5: 827-832.
37. Najbauer J, Huszthy PC, Barish ME, Garcia E, Metz MZ, et al. (2012) Cellular host responses to gliomas. PLoS One 7: e35150.
38. Daginakatte GC, Gutmann DH, (2007) Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet 16: 1098-1112.
39. Kokovay E, Goderie S, Wang Y, Lotz S, Lin G, et al. (2010) Adult SVZ lineage cells home to and leave the vascular niche via differential responses to SDF1/CXCR4 signaling. Cell Stem Cell 7: 163-173.
40. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, et al. (2012) Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget.
41. Takahashi K, Yamanaka S, (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676.
42. Beier D, Wischhusen J, Dietmaier W, Hau P, Proescholdt M, et al. (2008) CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol 18: 370-377.
43. Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, et al. (2010) Non-stem cell origin for oligodendroglioma. Cancer Cell 18: 669-682.
44. Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, et al. (2010) Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468: 567-571.
45. Palmer TD, Willhoite AR, Gage FH, (2000) Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 425: 479-494.
46. Fuentealba LC, Obernier K, Alvarez-Buylla A, (2012) Adult neural stem cells bridge their niche. Cell Stem Cell 10: 698-708.